JavaScript is disabled for your browser. Some features of this site may not work without it.
Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis
Title:Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis; Against Hepatitis B Recurrence After Liver Transplantation
Akarsu, M; Onem, S; Turan, I; Adali, G; Akdogan, M; Akyildiz, M; Aladag, M; Balaban, Y; Danis, N; Dayangac, M; Gencdal, G; Gokcan, H; Sertesen, E; Gurakar, M; Harputluoglu, M; Kabacam, G; Karademir, S; Kiyici, M; Idilman, R; Karasu, Z
The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence. However, the recommended doses, route of administration, and duration of HBIG administration remain unclear. Moreover, hepatitis B immunoglobulin-free prophylaxis with potent nucleos(t)ide analogs has shown promising disease outcomes in preventing hepatitis B virus recurrence. The current recommendations, produced by the Turkish Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t)ide analogs after liver transplantation.